Evaluation of cell free fetal DNA cffDNA extraction on the chemagic 360 instrument with the FetoGnost Kit RhD to determine fetal RhD status

Fetal Rhesus Factor D (RhD) genotyping is typically performed through non-invasive prenatal testing (NIPT) and is important in identifying RhD incompatibility between mother and child. NIPT avoids risks associated with invasive procedures such as amniocentesis or chorionic villus sampling and is performed with a simple blood draw to analyze cell free fetal DNA (cffDNA) present in the mother’s blood.

The FetoGnost® Kit RHD from Ingenetix allows rapid, sensitive, and non-invasive fetal RhD genotyping of samples purified from maternal plasma of RhD-negative pregnant women, based on real-time PCR technology. The chemagic™ automated nucleic acid isolation technology has been previously demonstrated to provide high and consistent yields of cell free DNA (cfDNA) from plasma when compared to manual column procedures.

Here, compatibility of the FetoGnost Kit RHD with extracted cffDNA obtained with the chemagic™ 360 instrument was tested using RhD-positive or -negative plasma from 36 blood donors.

For research use only. Not for use in diagnostic procedures.

*Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.